Retina

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

The authors commented that the patient’s "age, relative acute onset, and lack of medical history make this an atypical presentation.”

Maria Vittoria Cicinelli, MD, Denise Loya-Garcia, MD, PhD, and Vishal Raval, MD, were announced as the recipients and will receive a $3,000 honorarium.

The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease

ENCELTO is the first and only FDA-approved treatment for MacTel.

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly indicated for severe acute and chronic allergic and inflammatory conditions affecting the eye.

The negative effects of smoking on ocular tissues are well known and include age-related macular degeneration (AMD), diabetic retinopathy, cataracts, contact lens-related keratitis, Graves’ ophthalmopathy ischemic optic neuropathy, and glaucoma.

The investigators set out to identify a correlation between the TyG index in CRAO in patients who had been newly diagnosed with the disease.

Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.

The company announced it has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

Children experienced sudden vision loss, visual field constriction, nyctalopia and dyschromatopsia following febrile illness.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March.

Shah discusses several studies from the IRIS registry and plans for a retina program at next year's event to address the growing interest in retina procedures and techniques.

Advancements in drug durability and patient care are closing treatment gaps.

At the Envision Summit 2025 in San Juan, Puerto Rico, Nita Valikodath, MD, MS, gave insight into a challenging case of a 14-year-old boy who had trauma-related retinal detachment in his right eye, where a further macula-on retinal detachment with retinal dialysis was found in the left.

Researchers used data from the UK Biobank to investigate the associations between a healthy lifestyle score and retinal neurovascular health.

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.

Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free telemedicine and e-learning platform can significantly enhance care.

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial.

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will include retina discussions.

From cytokine pathways to genomics, Shree Kurup, MD, highlights new approaches for managing diabetic retinopathy and combating systemic inflammation.

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of 50 healthy controls

Researchers reported identifying changes in 4 areas of the brain

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.

Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.